

Alain Bergeron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3772085/publications.pdf>

Version: 2024-02-01

32
papers

4,099
citations

430754

18
h-index

434063

31
g-index

32
all docs

32
docs citations

32
times ranked

8009
citing authors

#	ARTICLE	IF	CITATIONS
1	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015, 163, 1011-1025.	13.5	2,435
2	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017, 541, 359-364.	13.7	462
3	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019, 176, 831-843.e22.	13.5	317
4	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	0.9	142
5	Bladder Tumor Infiltrating Mature Dendritic Cells and Macrophages as Predictors of Response to Bacillus Calmette-Guérin Immunotherapy. <i>European Urology</i> , 2009, 55, 1386-1396.	0.9	97
6	High frequency of MAGEA4 and MAGEA9 expression in high-risk bladder cancer. <i>International Journal of Cancer</i> , 2009, 125, 1365-1371.	2.3	77
7	Large-Scale Automatic Feature Selection for Biomarker Discovery in High-Dimensional OMICs Data. <i>Frontiers in Genetics</i> , 2019, 10, 452.	1.1	74
8	Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 881-892.	1.6	57
9	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , 2019, 25, 1615-1626.	15.2	45
10	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	0.9	37
11	MAGE-A9 mRNA and protein expression in bladder cancer. <i>International Journal of Cancer</i> , 2007, 120, 2170-2177.	2.3	36
12	Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas. <i>International Journal of Cancer</i> , 1990, 46, 990-997.	2.3	32
13	Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice. <i>Prostate</i> , 2019, 79, 9-20.	1.2	28
14	IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. <i>Research and Reports in Urology</i> , 2014, 6, 27.	0.6	26
15	The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival. <i>Prostate</i> , 2018, 78, 697-706.	1.2	25
16	Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 223-234.	2.0	23
17	Validation of the prognostic value of NF- κ B p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. <i>PLoS Medicine</i> , 2019, 16, e1002847.	3.9	23
18	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. <i>PLoS Medicine</i> , 2020, 17, e1003281.	3.9	19

#	ARTICLE	IF	CITATIONS
19	Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. <i>Radiation Oncology</i> , 2019, 14, 60.	1.2	18
20	MAUB Is a New Mucin Antigen Associated with Bladder Cancer. <i>Journal of Biological Chemistry</i> , 1996, 271, 6933-6940.	1.6	16
21	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. <i>BMC Urology</i> , 2018, 18, 78.	0.6	14
22	Cancer-testis antigen expression in bladder cancer. <i>Progres En Urologie</i> , 2006, 16, 421-8.	0.3	14
23	Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. <i>Cancer Prevention Research</i> , 2016, 9, 189-195.	0.7	11
24	Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5 α -reductase inhibitors. <i>BJU International</i> , 2018, 121, 399-404.	1.3	10
25	Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. <i>Molecular Cancer Research</i> , 2021, 19, 516-527.	1.5	10
26	Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer. , 1997, 71, 986-992.		9
27	Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 550894.	1.1	9
28	Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. <i>World Journal of Urology</i> , 2021, 39, 1549-1558.	1.2	9
29	Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. <i>Clinical and Translational Medicine</i> , 2022, 12, e581.	1.7	9
30	Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression. <i>Oncolmmunology</i> , 2020, 9, 1851950.	2.1	8
31	Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. <i>Journal of Biomedical Optics</i> , 2021, 26, .	1.4	4
32	Cystatin C for early detection of acute kidney injury after laparoscopic partial nephrectomy. <i>Urology Annals</i> , 2014, 6, 298.	0.3	3